undamentalytics Newsletter
Sign in

Envveno Medical Corp (NVNO) stock

Add to watchlist

Add holding +

NASDAQ: NVNO Nasdaq Health Care Equipment

Envveno Medical Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 4 sales by directors and officers, last 12 monthsInsider trades
  • Funds2 adding, 9 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Operating margin compressing: TTM operating margin fell to -24566.5%, down 20356.0pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 83.3% over the last 12 months.
  • Loss-making. Operating margin is -24566.5%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 20356.0 points on a year ago.
  • Burning cash. Free cash flow was -20037.4% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 3015.0% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 41.8% in a year.

Latest results: FY2019 Q4

Filed March 31, 2021
Earnings per share
-$6.29 against an average estimate of -$3.27: missed by 92.3%
Share reaction
-13.1% in the first session after the results on April 29, 2026, against +1.0% for the S&P 500

Envveno Medical's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.1%
  • 1 week+2.4%
  • 1 month-15.2%
  • This year-38.9%
  • 1 year-72.2%
  • 5 years-97.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-23.58

Earnings

Last results
April 29, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Envveno Medical Corp valuation models and calculator

No model value for Envveno Medical Corp at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$16.19 — — —
Next −$6.22 +62% — 0%

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$3.27 −$6.29 −92.3%
Jun 2026 −$4.69 −$5.37 −14.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611

Counts of recommendations published by analysts covering Envveno Medical Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
1.7%
of tradable shares
Days to cover
0.42
at average volume
Short interest, 1 month
+26%
to October 15, 2026
Held by institutions
16%
of shares
Held by insiders
8.1%
of shares
Employees
33
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
NVNO−24%−23%+1%−41%−89%−39%
Industry peers (median)−7%−37%−9%−19%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
NVNO33%33%58%33%50%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
NVNO−49%−52%−59%−63%−94%−49%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since May 31, 2018: 100% from May 31, 2018 to October 23, 2026. Getting back needed a 68847% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$6.65 – $24.85
From 52-week high
−72.4%
vs 50-day average
−22.7%
vs 200-day average
−33.1%
Volatility (1 year)
88%
Beta vs S&P 500
1.22

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 2 down
typical move ±20.3%
After a week
1 up, 2 down
typical move ±28.4%
After a month
2 up, 1 down
typical move ±21.1%
Results releasedNext dayS&P 500 next day5 days21 days
April 29, 2026 −13.1% +1.0% −16.2% −5.7%
February 4, 2026 −8.6% −1.7% −9.1% +12.0%
March 13, 2019 +39.3% +0.6% +60.0% +45.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Envveno Medical Corp
$0 $100K $200K $300K $400K FY18 Q1 FY18 Q3 FY19 Q1 FY19 Q4 Revenue (TTM), FY18 Q1: $272.9K Revenue (TTM), FY18 Q2: $317.4K Revenue (TTM), FY18 Q3: $331.2K Revenue (TTM), FY18 Q4: $186.6K Revenue (TTM), FY19 Q1: $186.7K Revenue (TTM), FY19 Q2: $103.4K Revenue (TTM), FY19 Q3: $61.7K Revenue (TTM), FY19 Q4: $31.2K $31.2K

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY18 Q1 $272.9K
FY18 Q2 $317.4K
FY18 Q3 $331.2K
FY18 Q4 $186.6K
FY19 Q1 $186.7K
FY19 Q2 $103.4K
FY19 Q3 $61.7K
FY19 Q4 $31.2K
Revenue growth, TTM YoY Envveno Medical Corp
-100% -50% 0% FY19 Q1 FY19 Q2 FY19 Q3 FY19 Q4 Revenue growth, TTM YoY, FY19 Q1: -31.6% Revenue growth, TTM YoY, FY19 Q2: -67.4% Revenue growth, TTM YoY, FY19 Q3: -81.4% Revenue growth, TTM YoY, FY19 Q4: -83.3% -83.3%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY19 Q1 -31.6%
FY19 Q2 -67.4%
FY19 Q3 -81.4%
FY19 Q4 -83.3%
Operating margin (TTM) Envveno Medical Corp
-30000% -20000% -10000% 0% FY18 Q1 FY18 Q3 FY19 Q1 FY19 Q4 Operating margin (TTM), FY18 Q1: -2356.1% Operating margin (TTM), FY18 Q2: -2617.6% Operating margin (TTM), FY18 Q3: -2410.7% Operating margin (TTM), FY18 Q4: -4210.5% Operating margin (TTM), FY19 Q1: -4273.9% Operating margin (TTM), FY19 Q2: -6606.4% Operating margin (TTM), FY19 Q3: -11628.3% Operating margin (TTM), FY19 Q4: -24566.5% -24566.5%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY18 Q1 -2356.1%
FY18 Q2 -2617.6%
FY18 Q3 -2410.7%
FY18 Q4 -4210.5%
FY19 Q1 -4273.9%
FY19 Q2 -6606.4%
FY19 Q3 -11628.3%
FY19 Q4 -24566.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019
Income
Revenue 0 0 0
Gross profit 0 0 —
EBITDA −6 −8 −8
Operating income −6 −8 −8
Net income −8 −13 −8
Diluted EPS −$1181.25 −$61.25 −$423.50
Growth (year on year)
Revenue — −55.8% −83.3%
Margins
Gross margin 0.6% 100.0% —
EBITDA margin <−999% <−999% <−999%
Operating margin <−999% <−999% <−999%
Net margin <−999% <−999% <−999%
Free-cash-flow margin −998.1% <−999% <−999%
Cash flow
Cash from operations −4 −6 −6
Capital spending 0 0 0
Free cash flow −4 −6 −6
Stock-based pay 1 2 1
Free cash flow after stock pay −5 −8 −7
Balance sheet
Cash 0 3 1
Total debt 2 0 0
Net debt (negative = net cash) 2 −3 −1
Diluted shares 7m 11m 18m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated NVNO CUPR POAS PAVM HSCS NXL Median
Revenue, last 12 months $31243 $38204 $102806 $112000 $4519 $217155 $95m
Revenue growth, last 12 months −83.3% 5.6% −18.2% −89.0% −64.2% 24.2% 9.1%
Revenue growth, 3-year average — — — −49.6% — −30.6% 13.5%
Revenue growth, latest quarter −100.0% — — 450.0% 10.5% −82.8% 9.9%
Gross margin 100.0% −1.3% 13.1% −220.5% 60.9% 86.2% 61.3%
Operating margin <−999% <−999% <−999% <−999% <−999% <−999% −8.7%
Operating margin, 3-year average — — — <−999% <−999% <−999% −17.9%
Net margin <−999% <−999% <−999% <−999% <−999% <−999% −12.1%
Cash from operations / revenue <−999% <−999% <−999% <−999% <−999% <−999% −2.1%
Free-cash-flow margin <−999% <−999% <−999% <−999% <−999% <−999% −4.0%
Free-cash-flow margin, 3-year average — — — <−999% — <−999% −7.0%
Stock pay / revenue >999% — — >999% >999% >999% 6.3%
Change in share count 41.8% 13.7% 19.7% 14.0% 200.7% 52.1% 4.0%

Median of all 135 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$953,622
Institutions reporting
17
Shares held vs prior quarter
▼ 11.7%
Positions opened / closed
2 / 3

Top buyers and sellers, Q2 2026: 2 institutions bought and 9 sold ; the biggest buyer was Mirae Asset Global Investments Co., Ltd (+539 shares) and the biggest seller Geode Capital Management, LLC (−10K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Kingdon Capital Management, L.L.C. $387,338 36K 40.6% 0.0%
Cm Management, LLC $382,497 36K 40.1% 0.0%
Vanguard Capital Management LLC $67,397 6K 7.1% 0.0%
Jpmorgan Chase & Co $59,111 5K 6.2% 0.0%
Vanguard Fiduciary Trust Co $23,412 2K 2.5% 0.0%
Westside Investment Management, Inc. $16,332 2K 1.7% ▼ 4.0%
Mirae Asset Global Investments Co., Ltd. $5,773 1K 0.6% New
Blackrock, Inc. $4,434 0K 0.5% ▼ 77.5%
Tower Research Capital LLC (TRC) $3,545 0K 0.4% ▼ 38.9%
Wells Fargo & Company $1,221 0K 0.1% 0.0%
Allied Private Wealth LLC $978 0K 0.1% —
Vanguard Global Advisers, LLC $825 0K 0.1% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Envveno Medical Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $4,944 4 trades by 1 insider · 100% under pre-set plans
Net ▼ $4,944 net selling
Insider Date Trade Shares Price Value
Duhay Francis Director September 11, 2026 Sell pre-set plan 11 $11.21 $123
Duhay Francis Director June 11, 2026 Sell pre-set plan 140 $10.31 $1,443
Duhay Francis Director March 12, 2026 Sell pre-set plan 140 $11.52 $1,613
Duhay Francis Director December 11, 2025 Sell pre-set plan 4,900 $0.36 $1,764

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • April 29, 2026
  • February 4, 2026
  • March 13, 2019

Recent SEC filings

Data status

When each part of this page on Envveno Medical Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Envveno Medical Corp in brief

What does Envveno Medical Corp do?
Envveno Medical Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Envveno Medical Corp's stock ticker?
Envveno Medical Corp trades under the ticker NVNO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Envveno Medical Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Kingdon Capital Management, L.L.C., Cm Management, LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Envveno Medical Corp's market cap?
On December 31, 2019, Envveno Medical Corp's market capitalisation was about $8.7B and net debt of -$1.3M. Market figures come from third-party market data and may be delayed.
Who are Envveno Medical Corp's competitors?
In our Health Care Equipment peer group, the companies closest to Envveno Medical Corp are Cuprina Holdings (cayman) LTD, Phaos Technology Holdings (cayman) Ltd, Pavmed Inc., Heartsciences Inc. and Nexalin Technology, Inc. The side-by-side comparison below sets their revenue, margins and growth against Envveno Medical Corp's.
Are insiders buying or selling Envveno Medical Corp stock?
Over the last 12 months, Envveno Medical Corp's directors and officers reported 0 open-market purchases and 4 sales on Form 4. The insider trading page charts every trade.